Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Tokyo, 113-8421, Japan.
Trends Pharmacol Sci. 2011 Oct;32(10):573-80. doi: 10.1016/j.tips.2011.06.001. Epub 2011 Jul 23.
Parkinson's disease (PD) is the second most common neurodegenerative disease. Mutations in PINK1 (PARK6) are the second most frequent cause of autosomal recessive, young-onset PD, after parkin (PARK2). PINK1 (a kinase with an N-terminal mitochondrial targeting sequence) provides protection against mitochondrial dysfunction and regulates mitochondrial morphology via fission/fusion machinery. PINK1 also acts upstream of parkin (a cytosolic E3 ubiquitin ligase) in a common pathway. Recent studies have described PINK1/parkin function in the maintenance of mitochondrial quality via autophagy (mitophagy). PINK1/parkin-mediated mitophagy provides new insights into the etiology of PD and could be a suitable target for new treatment of PD. In this review, we discuss the molecular genetics and functions of PINK1, which could be key factors in novel rational therapy for sporadic PD as well as PINK1-linked PD.
帕金森病(PD)是第二常见的神经退行性疾病。PINK1(PARK6)突变是继 parkin(PARK2)之后第二常见的常染色体隐性遗传、早发性 PD 的原因。PINK1(一种具有 N 端线粒体靶向序列的激酶)提供了对线粒体功能障碍的保护,并通过分裂/融合机制调节线粒体形态。PINK1 还在 parkin(一种细胞质 E3 泛素连接酶)的共同途径中起上游作用。最近的研究描述了 PINK1/parkin 通过自噬(mitophagy)在维持线粒体质量中的作用。PINK1/parkin 介导的 mitophagy 为 PD 的病因提供了新的见解,并且可能成为 PD 新治疗方法的合适靶点。在这篇综述中,我们讨论了 PINK1 的分子遗传学和功能,这可能是散发性 PD 以及与 PINK1 相关的 PD 的新型合理治疗的关键因素。